Efficacy and safety of sorafenib in patients with advanced clear-cell renal-cell carcinoma (RCC) with bone metastases: results from the phase III TARGET study

被引：0
|
作者：
Gschwend, J. E. [1 ]
Bukowski, R. [2 ]
Eisen, T. [3 ]
Stadler, W. S. [4 ]
Szczylik, C. S. [5 ]
Oudard, O. S. [6 ]
Siebels, M. S. [7 ]
Michel, M. S. [8 ]
Grimm, M. O. [9 ]
Escudier, B. E. [10 ]
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, Urol Klin & Poliklin, Munich, Germany
[2] Cleveland Clin Taussig Canc Ctr, Cleveland, OH USA
[3] Cambridge Res Inst, Cambridge, England
[4] Univ Chicago, Chicago, IL 60637 USA
[5] Mil Med Acad, Warsaw, Poland
[6] Hop Euopeen Georges Pompidou, Paris, France
[7] LMU, Klinikum Grosshadern, Munich, Germany
[8] Univ Klinikum Mannheim, Mannheim, Germany
[9] Klinikum Carl Gustav Carus, Dresden, Germany
[10] Inst Gustave Roussy, Villejuif, France
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：130 / 131
页数：2
相关论文
共 50 条
  • [21] Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study
    Vogelzang, Nicholas J.
    Olsen, Mark R.
    McFarlane, Joshua J.
    Arrowsmith, Edward
    Bauer, Todd M.
    Jain, Rohit K.
    Somer, Bradley
    Lam, Elaine T.
    Kochenderfer, Mark D.
    Molina, Ana
    Doshi, Gurjyot
    Lingerfelt, Brian
    Hauke, Ralph J.
    Gunuganti, Vijay
    Schnadig, Ian
    Van Veldhuizen, Peter
    Fleming, Mark
    Galamaga, Robert
    Gupta, Mukul
    Hool, Hugo
    Hutson, Thomas
    Zhang, Joshua
    McHenry, M. Brent
    Johansen, Jennifer L.
    Tykodi, Scott S.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (06) : 461 - +
  • [22] Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
    Johns, Andrew
    Campbell, Matthew T.
    Gao, Mamie
    Lim, Zita Dubauskas
    Wang, Emily
    Hahn, Andrew Warren
    Gao, Jianjun
    Shah, Amishi Yogesh
    Msaouel, Pavlos
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 419 - 419
  • [23] PHASE I/II STUDY OF DEXNIGULDIPINE AND DOXORUBICINE IN ADVANCED RENAL-CELL CARCINOMA (RCC)
    GEHLING, U
    WEIMAR, C
    SCHULER, U
    RATHGEB, F
    EHNINGER, G
    SCHUMACHER, K
    HAVEMANN, K
    FASEB JOURNAL, 1995, 9 (03): : A96 - A96
  • [24] Randomized phase iii trial of sorafenib in advanced renal cell carcinoma (RCC): Iimpact of crossover on survival
    Eisen, T.
    Bukowski, R.
    Staehler, M.
    Szczylik, C.
    S., Oudard
    Stadler, W.
    Simantov, R.
    Shan, M.
    Escudier, B.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 237 - 237
  • [25] Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival
    Eisen, T.
    Bukowski, R. M.
    Staehler, M.
    Szczylik, C.
    Oudard, S.
    Stadler, W. M.
    Schwartz, B.
    Simantov, R.
    Shan, M.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2006, 17 : 54 - 54
  • [26] Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC).
    Ravaud, A.
    Gardner, J.
    Hawkins, R.
    Von der Maase, H.
    Zantl, N.
    Harper, P.
    Rolland, F.
    Audhuy, B.
    Machiels, J.
    El-Hariry, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 217S - 217S
  • [27] Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study
    Bracarda, S.
    Choueiri, T. K.
    Powles, T.
    Motzer, R. J.
    Olencki, T.
    Frontera, O. A.
    Oudard, S.
    Rolland, F.
    Tomczak, P.
    Castellano, D.
    Appleman, L.
    Drabkin, H.
    Vaena, D.
    Milwee, S.
    Youkstetter, J.
    Escudier, B.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S196 - S196
  • [28] EFFICACY AND SAFETY OF SORAFENIB IN PTS WITH BRAIN AND BONE METASTASES: RESULTS FROM A LARGE OPEN-LABEL, NON-COMPARATIVE PHASE III STUDY OF SORAFENIB IN EUROPEAN PTS WITH ADVANCED RCC (EUARCCS)
    Bokemeyer, C.
    Porta, C.
    Beck, J.
    Negrier, S.
    Richel, D. J.
    Strauss, U. P.
    Burrock, K.
    Mersmann, S.
    Szczylik, C.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2008, 19 : 192 - 193
  • [29] Pembrolizumab: a beacon of hope for clear-cell renal-cell carcinoma patients post-nephrectomy
    Anand, Ayush
    Banda, Godfrey T.
    Satapathy, Prakasini
    Sharma, Rakesh Kumar
    Sharma, Divya
    Arora, Mithhil
    Khatib, Mahalaqua Nazli
    Gaidhane, Shilpa
    Zahiruddin, Quazi Syed
    Rustagi, Sarvesh
    INTERNATIONAL JOURNAL OF SURGERY OPEN, 2024, 62 (04) : 493 - 495
  • [30] Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET
    Negrier, S.
    Jaeger, E.
    Porta, C.
    McDermott, D.
    Moore, M.
    Bellmunt, J.
    Anderson, S.
    Cihon, F.
    Lewis, J.
    Escudier, B.
    Bukowski, R.
    MEDICAL ONCOLOGY, 2010, 27 (03) : 899 - 906
12345